This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


€1,100 savings expire in:

  • 00
  • 00
  • 00
  • 00
Europe's premier partnering event
November 4–6, 2024 | Stockholm, SwedenNovember 12–13, 2024 | Digital Partnering

Merck's EMEA Advance Biotech Grant at BIO-Europe

Take your company to new heights with Merck's EMEA Advance Biotech Grant Program

Through their EMEA Advance Biotech Grant Program, Merck recognize stand-out emerging biotech companies and helps them navigate their path to commercialization. Delivered as a dynamic competition, five selected biotech companies will have the opportunity to pitch their breakthroughs to Merck's Grant representatives and the overall BIO-Europe audience

More about Merck's EMEA Advance Biotech Grant

Merck understands the challenges emerging biotech companies face in the quest to push the next generation of drugs to market. This is why they have developed the Advance Biotech Grant programs which occurs on regular basis in different regions of the world. These programs awards grant recipients with products, services and consultation support to advance production and help accelerate their path to commercialization.

Apply. Interview. Pitch.

Ten (10) companies will be selected to proceed to an interview round with Merck. Following the interviews, five (5) companies will be chosen to advance to the pitch round at BIO-Europe. The winner and two (2) finalists will be selected on stage at BIO-Europe.

To be considered for the grant, Merck would like to see a description of your company's therapeutic focus, clinical strategy, and clear business strategy that outlines where Merck can help you overcome challenges and address gaps in expertise to bring your innovation to the finish line.

Product Criteria

  • Have at least one biologics in the pipeline
  • Must be developing new modalities or therapeutics products or offering an innovative service in:
    • mAbs
    • ADCs
    • mRNA
    • Gene Therapy
    • Cell Therapy
    • Vaccines
  • No program reaches PIII (or above development stages)

Company Criteria

  • Established over the last 20 years
  • Less than 500 employees
  • No more than €100 million in sales
  • Not a public institution (University, hospital, institutes or centers)
  • Looking for support and solution within their process development

Exclusion Criteria:

  • Any local, state, provincial or federal or other government or government agency or any officials or employees thereof
  • Any affiliates of Sponsor or any employees of Sponsor or its affiliates and their immediate family and household members
  • Healthcare organizations (HCOs), including hospitals, healthcare professionals (HCPs) and employees thereof
  • Excluding contract manufacturing or contract development and manufacturing organizations.


Program winner:
  • €148,400 in Bioprocessing technologies
  • M Ventures consultation, including contract testing services
  • One-year subscription to Emprove® Premium

  • €20,000 in Bioprocessing technologies
  • M Ventures consultation

Application timeline

Below you can review the application process and important deadlines.

September 9, 2024

Final day to submit your application.

September 10, 2024

Starting on this date, our team, together with Merck, will carefully review and consider all applications submitted.

September 16, 2024

Beginning on September 16, Merck will schedule interviews with the 10 companies chosen to move into this round.

October 1, 2024

Companies that have been selected to move to the live pitch round at BIO-Europe will be notified.

Term and Conditions

Please review Merck's Terms and Conditions here.